Tempol Mitigates Methotrexate-Induced Osteotoxicity via Oxidative Stress Modulation and MAPK Pathway Inhibition
Drug Design, Development and Therapy · 2025
DOI: 10.2147/dddt.s510206 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Fariz Selimli und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Mustafa Kemal University, Hatay, Turkey. Hauptthemen laut MEDLINE: Methotrexate, Cyclic N-Oxides, Oxidative Stress, MAP Kinase Signaling System. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral and Maxillofacial Surgery, Faculty of Dentistry, Mustafa Kemal University, Hatay, Turkey.
- Department of Medical Services and Techniques, Medical Promotion and Marketing Program, Medical Vocational Higher Services School, Nevsehir Haci Bektas University, Nevşehir, Turkey.
- Deparment of Medicinal Pharmacology, Faculty of Medicine, Cukurova University, Adana, Turkey.
ORCID-Profile: Halil Mahir Kaplan
Zitieren
APA
Selimli, F., Taş Reyhanioğlu, M., Haskan, A. C., Altun, M. S., Mete, S., & Kaplan, H. M. (2025). Tempol Mitigates Methotrexate-Induced Osteotoxicity via Oxidative Stress Modulation and MAPK Pathway Inhibition. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s510206
Vancouver
Selimli F, Taş Reyhanioğlu M, Haskan AC, Altun MS, Mete S, Kaplan HM. Tempol Mitigates Methotrexate-Induced Osteotoxicity via Oxidative Stress Modulation and MAPK Pathway Inhibition. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s510206
BibTeX
@article{Selimli2025,
author = {Selimli, Fariz and Taş Reyhanioğlu, Meryem and Haskan, Ahmet Can and Altun, Muhammed Said and Mete, Soner and Kaplan, Halil Mahir},
title = {Tempol Mitigates Methotrexate-Induced Osteotoxicity via Oxidative Stress Modulation and MAPK Pathway Inhibition},
journal = {Drug Design, Development and Therapy},
year = {2025},
doi = {10.2147/dddt.s510206}
}
EUVIMED